Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Defining reliable disability outcomes in multiple sclerosis.
Resting-State fMRI in MS: General Concepts and Brief Overview of Its Application.
Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L.
Anxiety state affects information processing speed in patients with multiple sclerosis.
Brain temperature in multiple sclerosis.
Synergistic Interactions between Cytokines and AVP at the Blood-CSF Barrier Result in Increased Chemokine Production and Augmented Influx of Leukocytes after Brain Injury.
Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.
Teriflunomide - a new oral agent for multiple sclerosis treatment.
How do corticosteroids influence myelin genesis in the central nervous system?
Participant perceptions of a novel physiotherapy approach ("Blue Prescription") for increasing levels of physical activity in people with multiple sclerosis: a qualitative study following intervention.
Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series.
1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities.
Multiple Roles for Nogo Receptor 1 in Visual System Plasticity.
Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation.
Role of myelin sheath energy metabolism in neurodegenerative diseases.
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun.
Hospital admission due to infections in multiple sclerosis patients.
EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis.
Bochum ultrasound score versus clinical and electrophysiological parameters in distinguishing acute-onset chronic from acute inflammatory demyelinating polyneuropathy.
Circulating Levels of Interleukin-35 in Patients with Multiple Sclerosis: Evaluation of the Influences of FOXP3 Gene Polymorphism and Treatment Program.
Defective structural RNA processing in relapsing-remitting multiple sclerosis.
Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.
The Effect of Biofeedback as a Psychological Intervention in Multiple Sclerosis: A Randomized Controlled Study.
Pages
« first
‹ previous
…
556
557
558
559
560
561
562
563
564
…
next ›
last »